Week In Review: I-Mab Partners CD47 With AbbVie In $2 Billion Deal

I-Mab out-licensed ex-China rights for lemzoparlimab, its anti-CD47 mAb, to AbbVie in a blockbuster $2 billion agreement. AbbVie also acquired right-of-first-refusal to two other CD47 molecules, which would each trigger a $500 million payment.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.